[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.194.83. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,700
Citations 0
Clinical Trials Update
June 25, 2019

Cariprazine Benefits Patients With Bipolar Depression

JAMA. 2019;321(24):2396. doi:10.1001/jama.2019.8399

Cariprazine, a dopamine and serotonin receptor partial agonist, was effective in reducing depressive symptoms in adults with bipolar I depression, according to a phase 3 trial in the American Journal of Psychiatry. Few effective treatments are available for patients with bipolar depression, and those currently used can cause mania.

The 488 patients were randomly assigned to receive cariprazine at 1.5 mg per day, 3.0 mg per day, or to placebo for 6 weeks. Depressive symptoms were measured by the Montgomery-Åsberg Depression Rating Scale (MADRS).

×